Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: A comparison of over-the-counter doses of proton pump inhibitors

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 8, 2010, Pages 846-851

  Miner Jr , P B ^a   McKean, L A ^b   Gibb, R D ^b   Erasala, G N ^b   Ramsey, D L ^b   McRorie, J W ^b  

^a Oklahoma Foundation for Digestive Research   (United States)

^b PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; NON PRESCRIPTION DRUG; OMEPRAZOLE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTRIC PH MONITORING; HUMAN; HUMAN EXPERIMENT; MALE; MEAL; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTACIDS; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS; OMEPRAZOLE; PROTON PUMP INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949685561     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04258.x     Document Type: Article

References (11)

1. Eisen G. Epidemiology and natural history of GERD. Am J Gastroenterol 2001 96 (8, supplement S16 8.
2. AC Nielsen/SmithKlineBeecham Survey. Profile of consumers in need: people with sour stomachs, by demographics. Progressive Groc 1995 74 : 98 9.
3. Miner PB, Allgood LD, Grender JM. Comparison of gastric pH with omeprazole magnesium 20.6mg (Prilosec OTC) o.m. famotidine 10mg (Pepcid AC) b.d. and famotidine 20mg b.d. over 14 days of treatment. Aliment Pharmacol Ther 2006 25 : 103 109.
4. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterol 2008 134 : 1842 1860.
5. Ratkowsky DA, Evans MA, Alldredge JR. Cross-over Experiments: Design, Analysis, and Application. New York : Marcel Dekker, Inc., 1993.
6. Miner P, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003 98 : 2616 2620.
7. Howden CW. Optimizing the pharmacology of acid control in acid-related disorder. Am J Gastroenterol 1997 92 : 17S 21S.
8. Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitor - Comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009 65 : 19 31.
9. Shimatani T, Inoue M, Kuroiwa T, et al. Acid-suppressive effects of rabeprazole, omeprazole, and lasoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Ther 2006 79 : 144 152.
10. Tolman KG, Sanders SW, Buchi KN, et al. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997 24 : 65 70.
11. Blum RA, Shi H, Karol MD, Greski-Rose PA, Hunt RH. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 1997 19 : 1013 1023.